While You Were Sipping Mint Juleps

We're not sure it's the 'most exciting two minutes in sports' as the Kentucky Derby bills itself (there were a few minutes in Saturday night's Flyers/Canadiens game that may have qualified though) but it's hard to argue with any sport associated with such a delicious beverage. We've traded our mint juleps for some cava out here in Barcelona, where a few of your IN VIVO Bloggers are attending Windhover's Euro Biotech Forum. We'll try to bring you some updates later this week. Meanwhile, over a quiet weekend in industryland ...

• BMS continues to part with anything that isn't core to its biopharmaceutical efforts. Late on Friday the company said it was offloading its wound care and ostomy care business to a private equity duo for $4.1 billion. Analysts like the price that Nordic Capital Fund VII and Avista Capital Partners paid for the group, and the deal comes on the heels of the announced spin-out of nutritionals group Mead Johnson. We're just eager to see what Bristol's going to do with all that cash. Reuters and the FT have the story.


• Forbes' Science Business blog recaps the state of the Merck/Schering-Plough relationship, and why SGP has a bit of a raw deal. (h/t Pharmagossip)

image from flickr user rcrowley used under a creative commons license